Skip to main content
. 2019 Jun 3;26(3):825–834. doi: 10.1038/s41380-019-0446-9

Table 2.

Clinical demographics and brain-PAD results in the initial categorization of patients

TLE-NL (N = 164) TLE-HS (N = 63) Ext-FE (N = 45) IGE (N = 30) SGE/PME (N = 5) PNES (N = 11)
Age (y)
 Mean ± SD 45.8 ± 16.6 43.3 ± 13.7 35.9 ± 12.0 28.9 ± 7.7 31.4 ± 9.8 31.5 ± 8.6
Sex (N)
 Male:female 81:83 25:38 27:18 8:22 3:2 3:8
Disease duration (y)
 Mean onset age ± SD 30.8 ± 20.8 14.4 ± 10.9 13.3 ± 10.5 15.6 ± 6.1 10.6 ± 8.7 23.6 ± 11.1
 Mean duration ± SD 15.0 ± 13.9 29.0 ± 13.5 22.6 ± 12.6 13.3 ± 9.3 20.8 ± 15.7 7.8 ± 7.3
Drug-resistance (N, %)
 Patients with refractory SZ 149 (91%) 61 (97%) 43 (96%) 6 (20%) 5 (100%) 11 (100%)
Brain-age estimation (y)
 Mean brain-PAD ± SD 4.7 ± 7.9 8.8 ± 7.3 5.6 ± 7.5 8.9 ± 6.3 21.2 ± 10.0 10.6 ± 5.6
 Estimated marginal mean ± SE 3.3 ± 0.5 6.9 ± 0.8 2.1 ± 0.9 3.8 ± 1.1 16.7 ± 2.7 6.1 ± 1.8

TLE-NL temporal lobe epilepsy with visually normal MRI, TLE-HS temporal lobe epilepsy with hippocampal sclerosis, Ext-FE extra-temporal lobe focal epilepsy, IGE idiopathic generalized epilepsy, SGE/PME symptomatic generalized epilepsy or progressive myoclonic epilepsy, PNES psychogenic nonepileptic seizures, SZ seizures, brain-PAD brain-predicted age difference, SE standard error